Literature DB >> 619076

Influenza immunization in immunosuppressed children.

P A Gross, H Lee, J A Wolff, C B Hall, A B Minnefore, M E Lazicki.   

Abstract

Optimal influenza immunization of individuals with malignancy and other immunodeficient states requires and understanding of responses to currently recommended regimens. Children with acute lymphocytic leukemia and other malignancies between three and 17 years of age were immunized with bivalent influenza vaccine containing A/New Jersey/76 and A/Victoria/75. Folowing a two-dose immunization schedule, only 37% (25468) on cancer chemotherapy seroconverted to a hemagglutination inhibition titer greater than or equal to 20 for A/NJ/76; the seroconversion rate in those not on chemotherapy was 92% (68/74, P less than 0.001). The immune response to the A/Vic/75 antigen was also related to a history of recent chemotherapy. There was no correlation between the immune response and the peripheral white blood cell count except at counts less than or equal to 1,000. The optimum time to immunize children with malignancies is when they have been off chemotherapy for one month and have peripheral white blood counts greater than 1,000.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 619076     DOI: 10.1016/s0022-3476(78)80065-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

1.  Decrease of CD4+ and B-lymphocyte populations is not associated with severe infectious complications in children with acute lymphoblastic leukemia during maintenance.

Authors:  Stavroula Kostaridou; Sophia Polychronopoulou; Katherine Psarra; Violetta Kapsimali; Agapi Parcharidou; Prokopis Katevas; Chrysa Papasteriades; Stavros Haidas
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

2.  Immune response to influenza vaccination in children with cancer.

Authors:  Dimitrios Doganis; Athanasia Kafasi; Helen Dana; Nikolaos Spanakis; Margarita Baka; Apostolos Pourtsidis; Triantafyllia Sdogou; Artemis Vintila; Vaia Rafailidou; Panagiota Chantzi; Marina Servitzoglou; Despina Bouhoutsou; Maria Varvoutsi; Helen Kosmidis; Maria Tsolia
Journal:  Hum Vaccin Immunother       Date:  2018-06-08       Impact factor: 3.452

3.  Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer.

Authors:  Yiqing Xu; Nanda Methuku; Praveena Coimbatore; Theresa Fitzgerald; Yiwu Huang; Ying-Yi Xiao; Murali Pagala; Shachi Gupta; William Solomon; Philip Rubin; John Treanor; Alan Astrow; Howard Minkoff; Jay S Cooper
Journal:  Oncologist       Date:  2012-01-12

Review 4.  Influenza vaccination in children being treated with chemotherapy for cancer.

Authors:  Ginette M Goossen; Leontien C M Kremer; Marianne D van de Wetering
Journal:  Cochrane Database Syst Rev       Date:  2013-08-01

5.  Response to influenza immunisation during treatment for cancer.

Authors:  J C Chisholm; T Devine; A Charlett; C R Pinkerton; M Zambon
Journal:  Arch Dis Child       Date:  2001-06       Impact factor: 3.791

Review 6.  Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus?

Authors:  Neerja Narula; Deborah L R Yamamura; John K Marshall
Journal:  Can J Gastroenterol       Date:  2010-02       Impact factor: 3.522

7.  Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus.

Authors:  R J Diepersloot; K P Bouter; W E Beyer; J B Hoekstra; N Masurel
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

Review 8.  Protecting pediatric oncology patients from influenza.

Authors:  Leslie S Kersun; Anne F Reilly; Susan E Coffin; Kathleen E Sullivan
Journal:  Oncologist       Date:  2013-01-31

9.  Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection.

Authors:  Hana Hakim; Kim J Allison; Lee-Ann Van de Velde; Li Tang; Yilun Sun; Patricia M Flynn; Jonathan A McCullers
Journal:  Vaccine       Date:  2016-04-26       Impact factor: 3.641

10.  Complement fixing antibody responses to virus infection in children with acute lymphoblastic leukaemia.

Authors:  A W Craft; M M Reid; J McQuillin; P S Gardner
Journal:  J Clin Pathol       Date:  1980-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.